Literature DB >> 9550598

Familial hemiplegic migraine with irreversible brain damage.

R Hayashi1, H Tachikawa, R Watanabe, M Honda, Y Katsumata.   

Abstract

Familial hemiplegic migraine (FHM) is an autosomal dominant syndrome characterized by recurrent episodes of varying degrees of hemiparesis associated with migraine. The aura including hemiparesis may be prolonged and in severe attacks may often be associated with confusion or coma. We describe a case of FHM whose aura was atypically prolonged and resulted in irreversible brain deficit which on magnetic resonance imaging (MRI) was suggestive of cortical hyperperfusion. A subsequent MRI showed left brain atrophy.

Entities:  

Mesh:

Year:  1998        PMID: 9550598     DOI: 10.2169/internalmedicine.37.166

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  5 in total

Review 1.  Sporadic hemiplegic migraine.

Authors:  David F Black
Journal:  Curr Pain Headache Rep       Date:  2004-06

2.  Sporadic hemiplegic migraine with permanent neurological deficits.

Authors:  Todd J Schwedt; Jiying Zhou; David W Dodick
Journal:  Headache       Date:  2013-10-10       Impact factor: 5.887

3.  Migrainous infarction in an adult: evaluation with serial diffusion-weighted images and cerebral blood flow studies.

Authors:  Syouichi Arai; Hidetsuna Utsunomiya; Shoji Arihiro; Shuji Arakawa
Journal:  Radiat Med       Date:  2008-07-27

4.  A G301R Na+/K+ -ATPase mutation causes familial hemiplegic migraine type 2 with cerebellar signs.

Authors:  Maria Spadaro; Simona Ursu; Frank Lehmann-Horn; Liana Veneziano; Veneziano Liana; Giovanni Antonini; Antonini Giovanni; Paola Giunti; Giunti Paola; Marina Frontali; Karin Jurkat-Rott
Journal:  Neurogenetics       Date:  2004-07-31       Impact factor: 2.660

5.  Familial and sporadic hemiplegic migraine: diagnosis and treatment.

Authors:  Nadine Pelzer; Anine H Stam; Joost Haan; Michel D Ferrari; Gisela M Terwindt
Journal:  Curr Treat Options Neurol       Date:  2013-02       Impact factor: 3.598

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.